Results 31 to 40 of about 98,296 (378)

Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents [PDF]

, 2014
Bone metastases in advanced cancer frequently cause painful complications that impair patient physical activity and negatively affect quality of life. Pain is often underreported and poorly managed in these patients.
A Kretzschmar, A Mañas, A Wardley, AT Stopeck, C Langer, C Logothetis, Charles S. Cleeland, CI Ripamonti, CJ Logothetis, CS Cleeland, CS Cleeland, D Henry, D Patrick, DH Henry, DL Patrick, Donald L. Patrick, DS Ernst, E Basch, E Chow, F Saad, F Saad, G Apolone, G Cartenì, G Storto, GN Hortobagyi, GN Hortobagyi, HI Scher, JJ Body, JJ Body, K Altundag, K Fizazi, K Harris, Katarina Öhrling, KC Chung, KP Weinfurt, KP Weinfurt, L Atahan, L Costa, L Fallowfield, Lesley Fallowfield, LS Matza, LS Rosen, LS Rosen, LS Rosen, M Huisman, M Martin, M Tomblyn, MG Lam, MJ Fisch, N Kohno, N Takeda, P Hoskin, P Hoskin, R Moos von, R Moos von, Rachel Wei, RE Coleman, RE Coleman, RE Coleman, RH Dworkin, RL Theriault, Roger von Moos, S Deandrea, S Nilsson, S Vadhan-Raj, SD Mathias, T Kijima, V Vassiliou, V Vassiliou, Yi Qian   +69 more
core   +1 more source

Cellular and molecular mediators of bone metastatic lesions [PDF]

, 2018
Bone is the preferential site of metastasis for breast and prostate tumor. Cancer cells establish a tight relationship with the host tissue, secreting factors that stimulate or inhibit bone cells, receiving signals generated from the bone remodeling ...
Battafarano, Giulia, Del Fattore, Andrea, Marampon, Francesco, Rossi, Michela   +3 more
core   +5 more sources

Prevention of osteoporotic refractures in regional Australia [PDF]

, 2017
Objective: Clinical guidelines recommend that patients who sustain a minimal trauma fracture (MTF) should receive a bone mineral density (BMD) scan and bisphosphonate (or equivalent) therapy if diagnosed with osteoporosis.
Davidson, E, Doyle, Z, Fielding, K, McGirr, J, Seal, A   +4 more
core   +2 more sources

Bisphosphonate conjugation for bone specific drug targeting

Bone Reports, 2018
Bones provide essential functions and are sites of unique biochemistry and specialized cells, but can also be sites of disease. The treatment of bone disorders and neoplasia has presented difficulties in the past, and improved delivery of drugs to bone ...
Kristen B. Farrell, Alexander Karpeisky, Douglas H. Thamm, Shawn Zinnen   +3 more
doaj   +1 more source

Mechanism of bisphosphonate-related osteonecrosis of the jaw (BRONJ) revealed by targeted removal of legacy bisphosphonate from jawbone using competing inert hydroxymethylene diphosphonate

eLife, 2022
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) presents as a morbid jawbone lesion in patients exposed to a nitrogen-containing bisphosphonate (N-BP). Although it is rare, BRONJ has caused apprehension among patients and healthcare providers and
Hiroko Okawa, Takeru Kondo, Akishige Hokugo, Philip Cherian, Jesus J Campagna, Nicholas A Lentini, Eric C Sung, Samantha Chiang, Yi-Ling Lin, Frank H Ebetino, Varghese John, Shuting Sun, Charles E McKenna, Ichiro Nishimura   +13 more
doaj   +1 more source

Regioselective ester cleavage during the preparation of bisphosphonate methacrylate monomers

Beilstein Journal of Organic Chemistry, 2011
New functional monomers bearing a methacrylate, a bisphosphonate function and, for most, an internal carboxylate group, were prepared for incorporation into copolymers with adhesive or anticorrosive properties.
Kamel Chougrani, Gilles Niel, Bernard Boutevin, Ghislain David   +3 more
doaj   +1 more source

Bisphosphonate-associated Osteonecrosis of the Jaws: a Survey of the Level of Knowledge of Dentists about the Risks of Bisphosphonate Therapy

Folia Medica, 2019
Introduction: Bisphosphonate-associated osteonecrosis of the jaws (BAONJ) is a side effect of treatment with bisphosphonate (BP). Reports of this complication have increased recently.
Hristamyan-Cilev Meri A., Pechalova Petya P., Raycheva Ralitsa D., Hristamyan Veselka P., Kevorkyan Ani K., Stoilova Yordanka D.   +5 more
doaj   +1 more source

Etidronate as A Weak Chelating Agent on Root Canal Dentin: An Update Review [PDF]

Journal of Clinical and Diagnostic Research, 2017
Successful root canal treatment depends on proper biomechanical cleaning and shaping of root canal system followed by threedimensional obturation. Irrigation solutions and chelating agents are used during root canal treatment to assist in smear layer ...
Samah Samir Bedir, Hossam Mossa, Ahmed Mohammed Hassan   +2 more
doaj   +1 more source

Tiludronate and clodronate do not affect bone structure or remodeling kinetics over a 60 day randomized trial [PDF]

, 2018
Background Tiludronate and clodronate are FDA-approved bisphosphonate drug therapies for navicular disease in horses. Although clinical studies have determined their ability to reduce lameness associated with skeletal disorders in horses, data regarding
Gillett, Ashley N., McNulty, Margaret A., Mitchell, Colin F., Richbourg, Heather A.   +3 more
core   +1 more source

Safety of bisphosphonates

Bone, 2011
Bisphosphonates are one of the most well studied groups of medications and they are bone specific. This tissue specificity is a rare property for a drug introduced into clinical practice as long as 40 years ago. Over the years, the therapeutic boundaries of bisphosphonates were explored and their safety profile has withstood the challenges of the harsh
Bo Abrahamsen, Bo Abrahamsen, Michael Pazianas   +2 more
openaire   +5 more sources